These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26632845)

  • 21. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth.
    Fillmore RA; Mitra A; Xi Y; Ju J; Scammell J; Shevde LA; Samant RS
    Int J Cancer; 2009 Aug; 125(3):556-64. PubMed ID: 19358268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
    Wang H; He L; Ma F; Regan MM; Balk SP; Richardson AL; Yuan X
    J Biol Chem; 2013 Mar; 288(9):6478-87. PubMed ID: 23306204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling.
    Zhou XL; Qin XR; Zhang XD; Ye LH
    Acta Pharmacol Sin; 2010 Feb; 31(2):202-10. PubMed ID: 20139903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
    Yang ZQ; Liu G; Bollig-Fischer A; Haddad R; Tarca AL; Ethier SP
    Int J Cancer; 2009 Oct; 125(7):1613-21. PubMed ID: 19569235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells.
    Voloshanenko O; Schwartz U; Kranz D; Rauscher B; Linnebacher M; Augustin I; Boutros M
    Sci Rep; 2018 Feb; 8(1):3178. PubMed ID: 29453334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling.
    Herbst A; Jurinovic V; Krebs S; Thieme SE; Blum H; Göke B; Kolligs FT
    BMC Genomics; 2014 Jan; 15():74. PubMed ID: 24467841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression.
    Roarty K; Pfefferle AD; Creighton CJ; Perou CM; Rosen JM
    Oncogene; 2017 Oct; 36(43):5958-5968. PubMed ID: 28650466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ror2 Signaling and Its Relevance in Breast Cancer Progression.
    Bayerlová M; Menck K; Klemm F; Wolff A; Pukrop T; Binder C; Beißbarth T; Bleckmann A
    Front Oncol; 2017; 7():135. PubMed ID: 28695110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of intracellular calcium by multiple Wnt ligands and translocation of β-catenin into the nucleus: a convergent model of Wnt/Ca2+ and Wnt/β-catenin pathways.
    Thrasivoulou C; Millar M; Ahmed A
    J Biol Chem; 2013 Dec; 288(50):35651-9. PubMed ID: 24158438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
    Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
    PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
    Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma.
    Lee SE; Lim SD; Kang SY; Suh SB; Suh YL
    Brain Pathol; 2013 Jul; 23(4):445-53. PubMed ID: 23278988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer.
    Jamal B; Sengupta PK; Gao ZN; Nita-Lazar M; Amin B; Jalisi S; Bouchie MP; Kukuruzinska MA
    Oral Oncol; 2012 Jun; 48(6):523-9. PubMed ID: 22341307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
    Prosperi JR; Goss KH
    Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 and microRNA-34 are suppressors of canonical Wnt signaling.
    Kim NH; Kim HS; Kim NG; Lee I; Choi HS; Li XY; Kang SE; Cha SY; Ryu JK; Na JM; Park C; Kim K; Lee S; Gumbiner BM; Yook JI; Weiss SJ
    Sci Signal; 2011 Nov; 4(197):ra71. PubMed ID: 22045851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.